Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BTCY 
Biotricity Inc (BTCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BTCY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.47% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.24M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.14 | 52 Weeks Range 0.19 - 0.83 | Updated Date 08/29/2025 |
52 Weeks Range 0.19 - 0.83 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-18 | When After Market | Estimate -0.11 | Actual -0.08 |
Profitability
Profit Margin -37.33% | Operating Margin (TTM) 7.28% |
Management Effectiveness
Return on Assets (TTM) -11.46% | Return on Equity (TTM) -4100.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43428122 | Price to Sales(TTM) 1.05 |
Enterprise Value 43428122 | Price to Sales(TTM) 1.05 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA -3.76 | Shares Outstanding 26567800 | Shares Floating 13875536 |
Shares Outstanding 26567800 | Shares Floating 13875536 | ||
Percent Insiders 39.37 | Percent Institutions 1.86 |
Upturn AI SWOT
Biotricity Inc
Company Overview
History and Background
Biotricity Inc. was founded in 2012 and focuses on developing medical-grade wearable biosensors for remote patient monitoring. The company aims to revolutionize preventive healthcare and chronic disease management.
Core Business Areas
- Remote Patient Monitoring (RPM) Solutions: Biotricity develops and markets medical-grade wearable sensors and software platforms for remote monitoring of chronic conditions, particularly cardiovascular diseases. Their solutions provide continuous monitoring of vital signs and transmit data to healthcare providers for analysis and intervention.
Leadership and Structure
Waqaas Al-Siddiq is the CEO of Biotricity. The company has a typical corporate structure with departments focusing on R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Bioflux: Bioflux is a wearable ECG monitor designed for early detection of cardiac abnormalities. It provides real-time monitoring and analysis of heart activity. Market share data is not readily available. Competitors include iRhythm Technologies (IRTC) and Preventice Solutions (acquired by Boston Scientific).
- Biotricity Platform: A software platform that aggregates and analyzes data from the Bioflux and other devices. It provides a comprehensive view of patient health. Market share data is not readily available. Competitors include Philips Healthcare, and Medtronic.
Market Dynamics
Industry Overview
The remote patient monitoring market is experiencing rapid growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in wearable technology. The industry is becoming increasingly competitive with many large and small players.
Positioning
Biotricity is positioned as a provider of medical-grade wearable biosensors and software platforms for remote patient monitoring. Its competitive advantage lies in its focus on developing highly accurate and reliable devices that meet the standards of the medical community.
Total Addressable Market (TAM)
The global remote patient monitoring market is expected to reach hundreds of billions of dollars. Biotricity is positioning itself to capture a portion of this market by focusing on high-accuracy monitoring for chronic conditions.
Upturn SWOT Analysis
Strengths
- Medical-grade wearable sensors
- Software platform for data analysis
- Focus on chronic disease management
Weaknesses
- Limited brand recognition
- High marketing costs
- Dependence on partnerships for distribution
Opportunities
- Growing demand for remote patient monitoring
- Partnerships with healthcare providers and payers
- Expansion into new markets
Threats
- Competition from larger players
- Regulatory changes
- Data security and privacy concerns
Competitors and Market Share
Key Competitors
- IRTC
- MDT
- BSX
Competitive Landscape
Biotricity faces competition from larger companies with greater resources and established market positions. Its ability to compete will depend on its ability to innovate and form strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Data on historical growth trends is unavailable. Further data is needed.
Future Projections: Future projections for Biotricity are not available with the current constraints.
Recent Initiatives: Recent initiatives include the development of new wearable sensors and expansion of the Biotricity platform.
Summary
Biotricity focuses on medical-grade wearable biosensors for remote patient monitoring and has a growing market. It is competitively positioned with its products like Bioflux. The company is small but faces competition from larger companies. Biotricity should focus on strategic partnerships and marketing to increase its market visibility.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- SEC Filings
Disclaimers:
The data and analysis provided are based on publicly available information and should not be considered financial advice. Market share data is estimated and may not be precise. The AI-based rating is an opinion and should be used for general information only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biotricity Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2016-02-18 | Founder, President, CEO & Chairman Dr. Waqaas Al-Siddiq Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 46 | Website https://www.biotricity.com |
Full time employees 46 | Website https://www.biotricity.com | ||
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which support medical practitioners to gather data, and regularly monitor and treat patients with two or more chronic care conditions; Bioheart that offers preventative care and disease management solutions; and Biokit, a remote patient monitoring kit for cardiac patients that had other chronic conditions such as hypertension or COPD. Biotricity, Inc. is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.